KR920702628A - 하이드록시아파타이트(hydroxyapatite)-항원 결합체 및 폴리-lg면역 반응을 일으키는 방법 - Google Patents

하이드록시아파타이트(hydroxyapatite)-항원 결합체 및 폴리-lg면역 반응을 일으키는 방법

Info

Publication number
KR920702628A
KR920702628A KR1019910701882A KR910701882A KR920702628A KR 920702628 A KR920702628 A KR 920702628A KR 1019910701882 A KR1019910701882 A KR 1019910701882A KR 910701882 A KR910701882 A KR 910701882A KR 920702628 A KR920702628 A KR 920702628A
Authority
KR
South Korea
Prior art keywords
antigen
immunogen
mammal
determinant
active ingredient
Prior art date
Application number
KR1019910701882A
Other languages
English (en)
Other versions
KR100188836B1 (ko
Inventor
장-삐에르 크래앙뷸
헬렌 엠. 아머롱겐
마리안 알. 뉴트라
Original Assignee
원본미기재
프레지던트 앤드 펠로우즈 오브 하바드 칼리지
앵스띠뛰 쉬스 드 르셰르쉬 엑스뻬리망딸 쉬르 르 깡세르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 프레지던트 앤드 펠로우즈 오브 하바드 칼리지, 앵스띠뛰 쉬스 드 르셰르쉬 엑스뻬리망딸 쉬르 르 깡세르 filed Critical 원본미기재
Publication of KR920702628A publication Critical patent/KR920702628A/ko
Application granted granted Critical
Publication of KR100188836B1 publication Critical patent/KR100188836B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

하이드록시아파타이트(hydroxyapatite)-항원 결합체 및 폴리 -1g면역 반응을 일으키는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1도는 M세포를 통해 세포간의 항원 이동을 개략적으로 나타낸 것이다.

Claims (13)

  1. 포유동물의 점막표면에 복합체를 투여하는 것으로 이루어지는, 포유동물에 활성성분에 투여하는 방법에 있어서, 상기 복합체가 하이드록실화된 칼슘 포스페이트와 함께 상기 활성성분을 포함하는 것을 특징으로 하는 방법.
  2. 제 1항에 있어서, 상기 하이드록실화된 칼슘 포스페이트가 상피를 통해 운반되기에 적당한 입자 형태로 존재하는 방법.
  3. 제 1항 있어서, 상기 복합체가 하이드록실화된 칼슘 포스테이트와 함께 항원 또는 항원 혼합물을 포함하는 면역원인 방법.
  4. 제 3항에 있어서, 상기 복합체를 투여함으로써 항원에 감각된 포유동물에서 ⅠgA-생성 임파아구가 생성되는 방법.
  5. 제 3항에 있어서, 면역원을 투여하여 항원이 존재하는 점막으로 주입된 약재에 대해 포유동물을 보호하도록 예방접촉하는 방법.
  6. 제 3항, 제 4항 또는 제 5항에 있어서, 상기 항원이 병원균 또는 정자의 외인성 결정인자를 포함하는 방법.
  7. 제 3항, 제 4항 또는 제 5항에 있어서, 상기 항원이 비루스성 도포 단백질, 비투스성 피막 단백질, 세포-표면 리포다당류, 또는 세포-표면 단백질인 방법.
  8. 제 3항, 제 4항 또는 제 5항에 있어서, 상기 면역원을 구강, 질, 코, 직장, 눈, 또는 중이로 투여하는 방법.
  9. 제 4항에 있어서, 상기 포유동물로부터 임파아구 대부분을 분리하여 영구히하고, 그리고 상기 영구임파아구중에서 항원에 특이하게 결합 가능한 ⅠgA를 분비하는 적어도하나의 영구임파아구를 식별하는 것을 부가로 포함하는 방법.
  10. 활성성분과 함께 상피를 통해 운반되기에 적당한 크기의 하이드록실화된 칼슘 포스페이트 미랍자와 함께 활성 성분을 포함하는 조성물.
  11. 제 10항에 있어서, 상기 복합체가 포유동물에서 점막 면역반응을 일으키기 위한 면역원이며, 상기 활성성분은 면역 반응이 필요한 항원의 결정인자를 포함하는 조성물.
  12. 항원의 결저인자가 병원균 또는 정자의 외인성 결정인자인 제 11항의 면역원.
  13. 제 12항에 있어서, 상기 항원의 결정인자가 비루스성 도포 단백질, 비루스성 피막 단백질, 세포-표면리포다당류, 또는 세포-표면 단백질의 결정인자인 면역원.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910701882A 1990-04-16 1991-04-16 하이드록시아파타이트-항원 복합체 및 폴리-ig면역반응을 일으키는방법 KR100188836B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7/510,154 1990-04-16
US07/510154 1990-04-16
US07/510,154 US5443832A (en) 1990-04-16 1990-04-16 Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
PCT/US1991/002599 WO1991016072A1 (en) 1990-04-16 1991-04-16 Hydroxyapatite-antigen conjugates and methods for generating a poly-ig immune response

Publications (2)

Publication Number Publication Date
KR920702628A true KR920702628A (ko) 1992-10-06
KR100188836B1 KR100188836B1 (ko) 1999-06-01

Family

ID=24029591

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701882A KR100188836B1 (ko) 1990-04-16 1991-04-16 하이드록시아파타이트-항원 복합체 및 폴리-ig면역반응을 일으키는방법

Country Status (16)

Country Link
US (2) US5443832A (ko)
EP (1) EP0477339B1 (ko)
JP (1) JPH04507106A (ko)
KR (1) KR100188836B1 (ko)
AT (1) ATE144428T1 (ko)
AU (1) AU643011B2 (ko)
BG (1) BG60371B1 (ko)
BR (1) BR9105718A (ko)
CA (1) CA2060318A1 (ko)
DE (1) DE69122828T2 (ko)
HU (1) HU216103B (ko)
OA (1) OA09525A (ko)
RO (1) RO109817B1 (ko)
RU (1) RU2126270C1 (ko)
WO (1) WO1991016072A1 (ko)
ZA (1) ZA912838B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
GB2245559A (en) * 1990-06-25 1992-01-08 Farmos Oy Bioceramic system for delivery of a bioactive compound.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US8333996B2 (en) * 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
JPH107575A (ja) * 1996-06-21 1998-01-13 Synsorb Biotec Inc 細菌性赤痢の処置
WO1997049431A2 (en) * 1996-06-21 1997-12-31 Synsorb Biotech, Inc. Use of oligosaccharides for neutralising e. coli toxins
US8728536B2 (en) * 1996-10-16 2014-05-20 Etex Corporation Chemotherapeutic composition using nanocrystalline calcium phosphate paste
JP2003517452A (ja) * 1999-02-05 2003-05-27 アルク−アベル・アー／エス 新規粘膜デリバリーシステム
US20020051794A1 (en) * 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU2006204620B2 (en) * 2000-09-14 2008-05-29 Px Biosolutions Pty Ltd Composition comprising immunogenic nanoparticles
AU2002248289A1 (en) * 2000-10-20 2002-09-04 Etex Corporation Chemotherapeutic composition using calcium phosphate paste
KR101161784B1 (ko) * 2003-04-11 2012-07-05 에텍스 코포레이션 골 유도성 골 물질
WO2005074991A1 (ja) * 2004-02-09 2005-08-18 Kabushiki Kaisha Sangi 抗腫瘍剤
WO2005100398A1 (ja) * 2004-04-14 2005-10-27 Bio Matrix Research Inc. 抗体ライブラリー作製方法
NZ550667A (en) * 2004-04-15 2010-10-29 Etex Corp Delayed-setting calcium phosphate pastes for the treatment of orthopedic conditions
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
EP1797900A1 (en) * 2004-10-07 2007-06-20 Kabushiki Kaisha Sangi Preparation for percutaneous/permucosal absorption
EP1872798B1 (en) * 2005-04-06 2013-06-05 Kabushiki Kaisha Sangi Intestinal absorptive anti-tumor agent
FR2885525B1 (fr) * 2005-05-13 2009-09-18 Urodelia Sa Medicament notamment anti-cancereux, destine a des traitements par immunotherapie, en particulier autologue
WO2007053781A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Compositions with antigens adsorbed to calcium phosphate
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
CA2710480A1 (en) * 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
GB201319548D0 (en) * 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses
TWI654993B (zh) * 2016-11-04 2019-04-01 National Health Research Institutes 陽離子型生物可降解性陶瓷聚合物微粒子用以遞送疫苗之用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3599150A (en) * 1969-08-01 1971-08-10 Miles Lab Stabilized aluminum hydroxide suspensions
US4016252A (en) * 1972-04-06 1977-04-05 Institut Pasteur Calcium phosphate gel for adsorbing vaccines
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
JPS59101145A (ja) * 1982-11-30 1984-06-11 日本特殊陶業株式会社 薬液含浸多孔質セラミツクス
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4757017A (en) * 1984-09-14 1988-07-12 Mcw Research Foundation, Inc. In vitro cell culture system
DK166762B1 (da) * 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
JPS62248487A (ja) * 1986-04-22 1987-10-29 Dentaru Kagaku Kk グルカナーゼを固定化したアパタイトおよびその製造法
JPS63196281A (ja) * 1987-02-12 1988-08-15 Sumitomo Electric Ind Ltd 細胞培養用基材
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
CN1057785A (zh) * 1990-04-16 1992-01-15 哈佛大学校长及研究员协会 合成多聚免疫球蛋白受体，受体-抗体复合物，生产及应用
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response

Also Published As

Publication number Publication date
CA2060318A1 (en) 1991-10-17
DE69122828D1 (de) 1996-11-28
AU643011B2 (en) 1993-11-04
US5443832A (en) 1995-08-22
HUT63337A (en) 1993-08-30
HU9200135D0 (en) 1992-04-28
ZA912838B (en) 1992-03-25
AU7684991A (en) 1991-11-11
OA09525A (en) 1992-11-15
ATE144428T1 (de) 1996-11-15
HU216103B (hu) 1999-04-28
BR9105718A (pt) 1992-07-21
JPH04507106A (ja) 1992-12-10
US6541000B1 (en) 2003-04-01
BG60371B1 (bg) 1994-11-15
DE69122828T2 (de) 1997-05-28
EP0477339B1 (en) 1996-10-23
WO1991016072A1 (en) 1991-10-31
BG95635A (bg) 1993-12-24
RO109817B1 (ro) 1995-06-30
KR100188836B1 (ko) 1999-06-01
EP0477339A1 (en) 1992-04-01
EP0477339A4 (en) 1993-04-21
RU2126270C1 (ru) 1999-02-20

Similar Documents

Publication Publication Date Title
KR920702628A (ko) 하이드록시아파타이트(hydroxyapatite)-항원 결합체 및 폴리-lg면역 반응을 일으키는 방법
Wu et al. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site
DE69418699T2 (de) Induktion der antworten zytotoxischer t-lymphozyten
Keizo et al. Immunochemical studies of phospholipids: III. Production of antibody to cardiolipin
AR003006A1 (es) Composición de vacuna combinada que comprende un polisacarido capsular de haemophilus influenzae b conjugado con una proteina portadora adsorbido sobre fosfato de aluminio y uno u otros antígenos distintos, métodos para producirla, y su uso para preparar un medicamento
ATE183198T1 (de) Immunogens gegen gonadotropin releasing hormone
BG99441A (en) Oral application of antigens
NO944475D0 (no) Kombinerte vaksiner omfattende Hepatit B overflateantigen og andre antigener
FI932561A (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
RS49890B (sr) Preparat u formi praška koji sadrži medicinsko sredstvo velike molekulske težine za primenu preko sluzokože
IL221708A0 (en) Polyclonal goat anti-hla class ii antibody for treatment of disease involving proliferative immune response
DK0588578T4 (da) Præparat, der indeholder både en oplöselig og en uoplöselig form af et immunogen
FI851859L (fi) Antigenpreparat och isolering av saodana preparat.
SE8404250D0 (sv) Antigen for tidig graviditetsprovning och kontraceptivt vaccin
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
Baca‐Estrada et al. The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization
PT97082A (pt) Processo para a preparacao de uma composicao farmaceutica contendo il-4,util para aumentar a resposta imunitaria a agressoes de antigenios infecciosos
DE69322960D1 (de) Empfängnisverhütender impfstoff
MY100476A (en) Supported viral antigen and preparation and use thereof
CA2389080A1 (en) Mistletoe lectins as mucosal adjuvants
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
Hall et al. IgG and IgA antibody in tears of rabbits immunized by topical application of ovalbumin.
EP0512023A4 (en) Medicaments and methods for treating aids and arc employing anti-carbohydrate antibodies and carbohydrate antigens
Takayama et al. Freeze-fracture immunocytochemistry for intracellular localization of serotonin in mast cells stimulated with compound 48/80
DE60025945D1 (de) Herstellung von antikörpern in mammarsekreten von zuchttieren

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee